Question · asked by 1 review
Gabapentin vs placebo: 'Substantial benefit' (≥ 50% reduction in pain or PGIC very much improved)
- Population
- people with diabetic peripheral neuropathy
- Intervention
- Gabapentin
- Comparison
- placebo
- Outcome
- 'Substantial benefit' (≥ 50% reduction in pain or PGIC very much improved)
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Gabapentin vs placebo Any definition of substantial benefit (at least 50% pain intensity reduction or PGIC very much improved) · adults with peripheral diabetic neuropathy Gabapentin for chronic neuropathic pain in adults (2017) · Cochrane Headline outcomes only | no estimate extracted | 6 studies · 1331 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Gabapentin for chronic neuropathic pain in adults 2017 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.